TScan Therapeutics cuts workforce 75% in reorganization to focus on in vivo solid tumor cell therapy
TCRX•Pipeline and trial updates
Phase 3 ALLOHA-2 enrollment for TSC-101 has been paused due to insufficient capital, with seven treated patients remaining in follow-up.
Two solid-tumor candidates have advanced to IND-enabling studies. The company is targeting its first IND for Q3 2027 and a Phase 1 start in Q4 2027.
Cash outlook and expected savings
TScan said cash, cash equivalents and marketable securities are expected to fund operations into Q4 2027.
The company projects cumulative cost savings of $55 million through 2027.
Strategic reorganization and workforce reduction
TScan Therapeutics launched a strategic reorganization to prioritize in vivo TCR-T cell therapy for solid tumors.
The company said it will cut its workforce by about 75%, eliminate internal manufacturing and reduce its research footprint.
